Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Opexa Therapeutics has announced that David McWilliams, president and CEO, has notified the company of his intention to retire following the naming of his successor.
Subscribe to our email newsletter
Scott Seaman, chairman of the Opexa’s nominations committee, said: “All of the directors would like to thank David for his valuable contributions to the company and for his generous commitment to continue to provide leadership during the search and transition period. We are also pleased that David will continue to serve on the board of directors and be part of advancing both our platforms, especially as we approach completion of the Tovaxin Phase IIb trial.”